RecruitingNot ApplicableNCT07121738
A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer
Sponsor
AdventHealth
Enrollment
64 participants
Start Date
Dec 8, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will examine the effects of an 8-week intervention called the Healthy Eating Active Lifestyle (HEAL)-GYN program on participants' 1) self-efficacy 2) lifestyle factors, including physical activity and diet, as well as mental health and overall well-being, and 3) biometrics and biomarkers.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria5
- Adult 18 years old or over
- Diagnosis of gynecologic cancer
- Current patient in the Central Florida area
- Completing or have completed chemotherapy treatment within approximately the past 3 months before starting the program
- Able to speak, read, and understand the English language.
Exclusion Criteria2
- Not willing or able to provide informed consent
- Not willing or able to comply with all study procedures and requirement for the duration of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALHealthy Eating Active Lifestyle (HEAL): Gyn Cancer Program
Evidence-based lifestyle medicine program for cancer survivors
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07121738
Related Trials
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
NCT070395261 location
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT0702478416 locations
Communication About Sexual Health in Gynecologic Cancer
NCT069043391 location
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT010340331 location
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
NCT075868261 location